Ironwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Ironwood Pharmaceuticals (NASDAQ:IRWD) issued its quarterly earnings data on Thursday. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01), FiscalAI reports. Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 37.48%. The business had revenue of $106.51 million during the quarter, compared to analyst estimates of $92.11 million.

Here are the key takeaways from Ironwood Pharmaceuticals’ conference call:

• LINZESS delivered a standout Q1 with 97% year‑over‑year U.S. net sales growth ($272.5M) driven by improved net price and 5% prescription demand growth, and management reiterated full‑year LINZESS U.S. net sales guidance of $1.125–$1.175 billion.
• The FDA has accepted a supplemental NDA for LINZESS in functional constipation for ages 2–5 with a priority review and PDUFA date of May 24, 2026, which could broaden the pediatric label if approved.
• Apraglutide is on track to initiate the confirmatory Phase III STARS 2 trial in Q2 (planned 124 patients, same primary endpoint at week 24); prior STARS data showed a ~twofold reduction in parenteral support and ~20% of patients in the long‑term extension achieved enteral autonomy, supporting a potential U.S. peak net‑sales opportunity of >$700M.
• Strong Q1 financials—GAAP net income of $40.8M, adjusted EBITDA of $76.7M, cash of $220.5M and plans to repay the June convertible note—management expects 2026 adjusted EBITDA >$300M and to reduce net debt to ~1x EBITDA by year‑end.
• Q1 net‑price gains were driven largely by elimination of inflationary rebates and favorable gross‑to‑net timing, and management expects an R&D ramp for STARS 2; these factors create execution and pricing risk that could pressure results if rebate dynamics or trial costs differ from assumptions.

Ironwood Pharmaceuticals Stock Performance

NASDAQ IRWD traded up $0.05 during trading on Friday, hitting $4.22. The stock had a trading volume of 2,547,764 shares, compared to its average volume of 2,216,940. The company has a market capitalization of $688.11 million, a PE ratio of 7.03 and a beta of 0.29. The company’s 50-day moving average price is $3.70 and its two-hundred day moving average price is $3.63. Ironwood Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $5.78.

Analyst Upgrades and Downgrades

IRWD has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, April 27th. Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Jefferies Financial Group restated a “hold” rating and issued a $3.70 target price on shares of Ironwood Pharmaceuticals in a research note on Thursday, February 26th. Citizens Jmp boosted their target price on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. Finally, Wall Street Zen cut Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ironwood Pharmaceuticals has an average rating of “Hold” and an average target price of $6.23.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, Director Alexander J. Denner sold 6,730,800 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $3.05, for a total value of $20,528,940.00. Following the sale, the director owned 9,188,635 shares in the company, valued at approximately $28,025,336.75. The trade was a 42.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in IRWD. AQR Capital Management LLC raised its stake in shares of Ironwood Pharmaceuticals by 535.8% during the 1st quarter. AQR Capital Management LLC now owns 2,523,875 shares of the biotechnology company’s stock worth $3,710,000 after purchasing an additional 2,126,889 shares in the last quarter. Millennium Management LLC raised its stake in shares of Ironwood Pharmaceuticals by 186.6% during the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after purchasing an additional 4,140,439 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Ironwood Pharmaceuticals during the 1st quarter worth approximately $57,000. Goldman Sachs Group Inc. raised its stake in shares of Ironwood Pharmaceuticals by 72.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,575,416 shares of the biotechnology company’s stock worth $2,316,000 after purchasing an additional 660,144 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Ironwood Pharmaceuticals by 740.5% during the 1st quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock worth $5,160,000 after purchasing an additional 3,092,475 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.